SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW is trending as the community rallies around its deflationary meme coin status, highlighting its multichain functionality across Solana, BSC, CRO, and ETH (BASE) via Layerzero. Community members are enthusiastically chanting "caw caw caw" and emphasizing the coin's fully circulated supply and organic growth.

Bonk refers to a series of comic-style memes in which meme characters such as Doge and Cheems get hit on the head with bats, hammers and other heavy objects, accompanied by the “Bonk” sound effect and clipart. The original image that spawned the meme depicts a Shiba Inu, named Copper. Bonk brings this humor on-chain, transforming the classic meme into a tokenized digital movement powered by community and culture.

Copper Inu

Copper Inu ($COPPER) is trending amid community discussions about its chart patterns and potential for a breakout, particularly in relation to other tokens like $SOL and $BTC. Some users are pointing to its name as indicative of strength, while others express concerns about potential scams.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending amidst mixed sentiment, with some users expressing frustration and others anticipating a potential uptrend. Community members are actively discussing trading strategies, staking, and the impact of broader market trends on CRO's performance, while also referencing the meme coin $CAW.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around this Solana-based meme coin, emphasizing its community-driven nature and long-term commitment with some holders staying strong for over a year. Conversations revolve around the playful "What's UpDog?" meme and promoting community engagement across various social media platforms to drive broader awareness.

Recall is a decentralized skill market for AI where communities fund, rank, and discover the AI solutions they need. Instead of corporations pushing one-size-fits-all AI, Recall flips the dynamic—communities signal demand, developers compete to deliver, and performance determines visibility.

Recall

RECALL CRYPTO is trending due to its recent ICO, with community members actively discussing its potential and current price action. High volume and new highs are fueling interest, though some caution against potential risks associated with new cryptocurrencies. The community is also comparing RECALL to other cryptocurrencies and exploring its potential within the broader crypto market.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is gaining traction as traders discuss its low float and potential for a short squeeze, with comparisons being drawn to other Hong Kong-based stocks that have recently experienced significant gains. Community members are highlighting the company's regained NASDAQ compliance and a substantial contract exceeding its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential staking opportunities and meme coin integrations within its ecosystem. Conversations highlight Solana's strong setup and positive trend, with some anticipating a potential move towards new highs. Community members are also closely watching various meme coins built on Solana, such as $CAW and $UPDOG.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending amid community discussions around its financial strategies, particularly the recent Bitcoin exchange for Semnur shares and investments in Datavault AI, leaving some investors wary. Concerns are rising about potential shareholder dilution and whether these moves will truly benefit the company's core business and Semdexa's progress. The stock's volatility and high short interest are also fueling speculation about a potential short squeeze.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending due to its upcoming listing on Kraken, generating excitement about increased accessibility and potential price movement. The community is actively discussing staking strategies and accumulating more tokens in anticipation of further exchange listings and long-term gains. Some users also highlight recent institutional investments and positive on-chain data as bullish signals.

Dominion Energy, Inc. engages in the production and distribution of energy. It operates through following business segments: Dominion Energy Virginia, Dominion Energy South Carolina, Contracted Energy, and Corporate and Other. The Corporate and Other segment focuses on corporate, service company, non-controlling interest in Dominion privatization, and non-regulated retail energy marketing operations. The company was founded by William W. Berry in 1983 and is headquartered in Richmond, VA.

Dominion Energy Inc

Dominion Energy is trending as investors weigh the impact of rising electricity demand from AI and data centers, alongside discussions about the company's dividend and strategic direction. The community is actively debating Dominion's potential within the evolving energy landscape, particularly in light of both bullish Elliott Wave analyses projecting significant upside and concerns around debt and renewable energy investments. Several analysts have adjusted their ratings and price targets, contributing to the ongoing conversation around the utility stock.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?

KROS vs. EXAS: Which Stock Is the Better Value Option?

Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? 

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo

GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-announces-review-strategic-alternatives">adopted</a> a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly accumulated a significant number of shares in the firm.The defense strategy, a limited-duration stockholder rights plan, will reduce the likelihood that a hostile group gains control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.As per the plan, if any entity acquires ownership of 10% or more, or 15% in the case of passive institutional investors, of Keros’ outstanding common stock in a transaction not approved by the Board, other shareholders can purchase additional shares at a discount.The company adopted the plan after a number of investors who accumulated the company’s common stock indicated a desire to gain control over the firm. This included an individual investor who informed the company that it holds 11.2% of Keros’ outstanding common stock as of April 6, 2025. The company did not name the investor.Keros said that its board has also decided to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the company.A committee will consider a range of strategic alternatives including the sale of the company or other business combination transaction, continued investment in its pipeline, or return of excess capital to stockholders.The company added that there is no assurance the review will lead to the company pursuing a transaction.On Stocktwits, retail sentiment around Keros jumped from ‘neutral’ to ‘extremely bullish’ while message volume rose from ‘low’ to ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:647/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_10_at_11_27_14_AM_png_386737346f.webp" alt="KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits" width="647" height="151"><figcaption>KROS's Sentiment Meter and Message Volume as of 11:30 a.m. ET on April 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/KROS">KROS shares</a> are down by about 26% year-to-date and 81% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/polestar-q1-sales-jump-76-percent-on-newer-models/chfYiCFRbBr">Polestar Q1 Sales Jump 76% On Newer Models: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed

The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.

Equity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$13.83
Prev Close	$13.74
Open	$13.77
Dividend Yield	0.00%
50-Day Moving Average	$15.24
Beta	0.95
Avg. Volume	324,372.90
PE Ratio	43.86

52-Week High	$72.37
52-Week Low	$9.12
Market Capitalization	$558.06M
EPS (Annual)	-$5.00
Price to Book	0.79
Revenue Per Employee	$21,005.92
Enterprise Value/EBITDA	N/A

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KROS News

KROSKeros Therapeutics Inc